Heike E Daldrup-Link

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4755593/publications.pdf

Version: 2024-02-01

304 papers	12,144 citations	25034 57 h-index	31849 101 g-index
334 all docs	334 docs citations	334 times ranked	13189 citing authors

#	Article	IF	Citations
1	PET/MR of pediatric bone tumors: what the radiologist needs to know. Skeletal Radiology, 2023, 52, 315-328.	2.0	1
2	One-stop local and whole-body staging of children with cancer. Pediatric Radiology, 2022, 52, 391-400.	2.0	4
3	How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol. Pediatric Radiology, 2022, 52, 354-366.	2.0	12
4	Artificial intelligence for bone cancer imaging. , 2022, , 75-90.		0
5	Pediatric PET/MRI Neuroimaging: Overview. , 2022, , 737-740.		0
6	In vivo imaging of nanoparticle-labeled CAR T cells. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	40
7	Disparate participation by gender of conference attendants in scientific discussions. PLoS ONE, 2022, 17, e0262639.	2.5	5
8	Diagnostic Accuracy of 2-[18F]FDG-PET and whole-body DW-MRI for the detection of bone marrow metastases in children and young adults. European Radiology, 2022, 32, 4967-4979.	4.5	11
9	Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nature Medicine, 2022, 28, 333-344.	30.7	105
10	Mechanoporation enables rapid and efficient radiolabeling of stem cells for PET imaging. Scientific Reports, 2022, 12, 2955.	3.3	2
11	Editorial to the Special Issue Entitled â€œImaging in Immunooncologyâ€• Molecular Imaging and Biology, 2022, 24, 177-180.	2.6	1
12	Web-Based Application for Biomedical Image Registry, Analysis, and Translation (BiRAT). Tomography, 2022, 8, 1453-1462.	1.8	5
13	Vascular injury of immature epiphyses impair stem cell engraftment in cartilage defects. Scientific Reports, 2022, 12, .	3.3	0
14	Pediatric Molecular Imaging. , 2021, , 1131-1147.		0
15	An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1522-1537.	6.4	6
16	Artificial intelligence enables whole-body positron emission tomography scans with minimal radiation exposure. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2771-2781.	6.4	45
17	Increasing Diversity in Radiology and Molecular Imaging: Current Challenges. Molecular Imaging and Biology, 2021, 23, 625-638.	2.6	8
18	Challenges and Initiatives in Diversity, Equity and Inclusion in Cancer Molecular Imaging. Frontiers in Oncology, 2021, 11, 638692.	2.8	2

#	Article	IF	Citations
19	Ascorbic Acid and Iron Supplement Treatment Improves Stem Cellâ€“Mediated Cartilage Regeneration in a Minipig Model. American Journal of Sports Medicine, 2021, 49, 1861-1870.	4.2	10
20	Clinical impact of PET/MRI in oligometastatic colorectal cancer. British Journal of Cancer, 2021, 125, 975-982.	6.4	17
21	The role of sex as a biological variable in the efficacy and toxicity of therapeutic nanomedicine. Advanced Drug Delivery Reviews, 2021, 174, 337-347.	13.7	21
22	Ferumoxytol magnetic resonance imaging detects joint and pleural infiltration of bone sarcomas in pediatric and young adult patients. Pediatric Radiology, 2021, 51, 2521-2529.	2.0	2
23	A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas. Molecular Cancer Therapeutics, 2021, 20, 2016-2025.	4.1	15
24	Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacological Research, 2021, 171, 105780.	7.1	196
25	PET/MRI Improves Management of Children with Cancer. Journal of Nuclear Medicine, 2021, 62, 1334-1340.	5.0	12
26	Can the biomolecular corona induce an allergic reaction?â€"A proof-of-concept study. Biointerphases, 2021, 16, 011008.	1.6	5
27	Validation of Deep Learningâ€“based Augmentation for Reduced ¹⁸F-FDG Dose for PET/MRI in Children and Young Adults with Lymphoma. Radiology: Artificial Intelligence, 2021, 3, e200232.	5.8	8
28	In Vivo Evaluation of Near-Infrared Fluorescent Probe for TIM3 Targeting in Mouse Glioma. Molecular Imaging and Biology, 2021, , 1.	2.6	2
29	Ferumoxytol Does Not Impact Standardized Uptake Values on PET/MR Scans. Molecular Imaging and Biology, 2020, 22, 722-729.	2.6	8
30	Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents. European Radiology, 2020, 30, 1790-1803.	4.5	16
31	Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI. Radiology, 2020, 296, 143-151.	7.3	28
32	Instant labeling of therapeutic cells for multimodality imaging. Theranostics, 2020, 10, 6024-6034.	10.0	17
33	Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRI. Theranostics, 2020, 10, 3612-3621.	10.0	24
34	Brain iron deposition after Ferumoxytol-enhanced MRI: A study of Porcine Brains. Nanotheranostics, 2020, 4, 195-200.	5.2	5
35	Tumor Formation of Adult Stem Cell Transplants in Rodent Arthritic Joints. Molecular Imaging and Biology, 2019, 21, 95-104.	2.6	12
36	Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell â€˜don't eat meâ€™ signals off and â€˜eat meâ€™ signals on. Molecular Oncology, 2019, 13, 2049-2061.	4.6	30

#	Article	IF	Citations
37	Pediatric Molecular Imaging. Pediatric Oncology, 2019, , 347-367.	0.5	0
38	Artificial intelligence applications for pediatric oncology imaging. Pediatric Radiology, 2019, 49, 1384-1390.	2.0	30
39	The yin and yang of imaging tumor associated macrophages with PET and MRI. Theranostics, 2019, 9, 7730-7748.	10.0	53
40	How to Prevent a Leaky Pipeline in Academic Radiology: Insights From a FacultyÂSurvey. Journal of the American College of Radiology, 2019, 16, 1220-1224.	1.8	5
41	Theranostic nanoparticles enhance the response of glioblastomas to radiation. Nanotheranostics, 2019, 3, 299-310.	5.2	13
42	GdVO₄:Eu³⁺,Bi³⁺ Nanoparticles as a Contrast Agent for MRI and Luminescence Bioimaging. ACS Omega, 2019, 4, 15806-15814.	3.5	17
43	Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. Cephalalgia, 2019, 39, 1407-1420.	3.9	22
44	Tracking Stem Cell Implants in Cartilage Defects of Minipigs by Using Ferumoxytol-enhanced MRI. Radiology, 2019, 292, 129-137.	7.3	28
45	Magnetic resonance imaging of stem cellâ€“macrophage interactions with ferumoxytol and ferumoxytolâ€derived nanoparticles. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2019, 11, e1552.	6.1	10
46	Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma. Cell Death and Disease, 2019, 10, 36.	6.3	72
47	Cover Image, Volume 11, Issue 4. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2019, 11, e1572.	6.1	0
48	Variability in billing practices for whole-body magnetic resonance imaging: reply to Degnan et al.. Pediatric Radiology, 2019, 49, 154-154.	2.0	1
49	Ferumoxytol Can Be Used for Quantitative Magnetic Particle Imaging of Transplanted Stem Cells. Molecular Imaging and Biology, 2019, 21, 465-472.	2.6	48
50	Quantification of Macrophages in High-Grade Gliomas by Using Ferumoxytol-enhanced MRI: A Pilot Study. Radiology, 2019, 290, 198-206.	7.3	61
51	Association of Tumor [18F]FDG Activity and Diffusion Restriction with Clinical Outcomes of Rhabdomyosarcomas. Molecular Imaging and Biology, 2019, 21, 591-598.	2.6	14
52	Neurovascular Unit: Basic and Clinical Imaging with Emphasis on Advantages of Ferumoxytol. Neurosurgery, 2018, 82, 770-780.	1.1	35
53	Bone marrow oedema predicts bone collapse in paediatric and adolescent leukaemia patients with corticosteroid-induced osteonecrosis. European Radiology, 2018, 28, 410-417.	4.5	14
54	Current utilization and procedural practices in pediatric whole-body MRI. Pediatric Radiology, 2018, 48, 1101-1107.	2.0	34

#	Article	IF	Citations
55	Ferumoxytol Is Not Retained in Kidney Allografts in Patients Undergoing Acute Rejection. Molecular Imaging and Biology, 2018, 20, 139-149.	2.6	13
56	Transfer learning on fused multiparametric MR images for classifying histopathological subtypes of rhabdomyosarcoma. Computerized Medical Imaging and Graphics, 2018, 65, 167-175.	5.8	62
57	How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1Âh: the Stanford Approach. Molecular Imaging and Biology, 2018, 20, 324-335.	2.6	29
58	The Protein Corona around Nanoparticles Facilitates Stem Cell Labeling for Clinical MR Imaging. Radiology, 2018, 286, 938-947.	7.3	27
59	Photoacoustic Imaging of Embryonic Stem Cellâ€Derived Cardiomyocytes in Living Hearts with Ultrasensitive Semiconducting Polymer Nanoparticles. Advanced Functional Materials, 2018, 28, 1704939.	14.9	58
60	Tracking Cell Transplants in Femoral Osteonecrosis with Magnetic Resonance Imaging: A Proof-of-Concept Study in Patients. Clinical Cancer Research, 2018, 24, 6223-6229.	7.0	21
61	Clinical Tracking of Cell Transfer and Cell Transplantation: Trials and Tribulations. Radiology, 2018, 289, 604-615.	7.3	87
62	Writing a review article - Are you making these mistakes?. Nanotheranostics, 2018, 2, 197-200.	5.2	9
63	Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation. Clinical Cancer Research, 2018, 24, 4110-4118.	7.0	77
64	Ferumoxytol-based Dual-modality Imaging Probe for Detection of Stem Cell Transplant Rejection. Nanotheranostics, 2018, 2, 306-319.	5.2	8
65	Detection of Stem Cell Transplant Rejection with Ferumoxytol MR Imaging: Correlation of MR Imaging Findings with Those at Intravital Microscopy. Radiology, 2017, 284, 495-507.	7.3	24
66	Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney International, 2017, 92, 47-66.	5.2	230
67	Next-generation superparamagnetic iron oxide nanoparticles for cancer theranostics. Drug Discovery Today, 2017, 22, 1421-1429.	6.4	113
68	The Fermi Paradox in STEMâ€"Where Are the Women Leaders?. Molecular Imaging and Biology, 2017, 19, 807-809.	2.6	9
69	Ten Things You Might Not Know about Iron Oxide Nanoparticles. Radiology, 2017, 284, 616-629.	7.3	129
70	Rethinking Brain Cancer Therapy: Tumor Enzyme Activatable Theranostic Nanoparticles. Molecular Imaging, 2017, 16, 153601211773095.	1.4	6
71	A PET/MR Imaging Approach for the Integrated Assessment of Chemotherapy-induced Brain, Heart, and Bone Injuries in Pediatric Cancer Survivors: A Pilot Study. Radiology, 2017, 285, 971-979.	7.3	9
72	How PET/MR Can Add Value for Children with Cancer. Current Radiology Reports, 2017, 5, 1.	1.4	22

#	Article	IF	Citations
73	A Novel Theranostic Strategy for MMP-14â€“Expressing Glioblastomas Impacts Survival. Molecular Cancer Therapeutics, 2017, 16, 1909-1921.	4.1	35
74	Whole-body PET/MRI of Pediatric Patients: The Details That Matter. Journal of Visualized Experiments, 2017, , .	0.3	3
75	Alk5 inhibition increases delivery of macromolecular and protein-bound contrast agents to tumors. JCI Insight, 2016, 1, .	5.0	13
76	Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults. Investigative Radiology, 2016, 51, 221-227.	6.2	64
77	Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nature Nanotechnology, 2016, 11, 986-994.	31.5	1,223
78	Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncology, The, 2016, 17, 1396-1408.	10.7	356
79	Macrophage phagocytosis alters the MRI signal of ferumoxytol-labeled mesenchymal stromal cells in cartilage defects. Scientific Reports, 2016, 6, 25897.	3.3	17
80	Speeding up PET/MR for cancer staging of children and young adults. European Radiology, 2016, 26, 4239-4248.	4.5	20
81	Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. Radiology, 2016, 280, 905-915.	7.3	39
82	White Paper on P4 Concepts for Pediatric Imaging. Journal of the American College of Radiology, 2016, 13, 590-597.e2.	1.8	11
83	Progressing Toward a Cohesive Pediatric 18F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?. Journal of Nuclear Medicine, 2016, 57, 70-77.	5.0	15
84	Imaging Tumor Necrosis with Ferumoxytol. PLoS ONE, 2015, 10, e0142665.	2.5	32
85	Magnetic Resonance Imaging of Stem Cell Apoptosis in Arthritic Joints with a Caspase Activatable Contrast Agent. ACS Nano, 2015, 9, 1150-1160.	14.6	67
86	Improved Approach for Chondrogenic Differentiation of Human Induced Pluripotent Stem Cells. Stem Cell Reviews and Reports, 2015, 11, 242-253.	5.6	99
87	Value of ¹⁸F-FDG PET and PET/CT for Evaluation of Pediatric Malignancies. Journal of Nuclear Medicine, 2015, 56, 274-286.	5.0	101
88	Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors. Nanomedicine, 2015, 10, 993-1018.	3.3	98
89	Reply to Dr. Vazquez et al. regarding current methods for reducing intussusception: external manual reduction with US assistance. Pediatric Radiology, 2015, 45, 1262-1262.	2.0	0
90	Current methods for reducing intussusception: survey results. Pediatric Radiology, 2015, 45, 667-674.	2.0	46

#	Article	IF	Citations
91	Lymphoid follicular hyperplasia. , 2014, , 215-217.		1
92	MR Imaging of Stem Cell Transplants in Arthritic Joints. Journal of Stem Cell Research & Therapy, 2014, 04, 165.	0.3	9
93	Successful Treatment with Temozolomide Combined with Chemoradiotherapy and Surgery of a Metastatic Undifferentiated Soft Tissue Sarcoma with Relapse in the Central Nervous System of a Young Adult. Journal of Adolescent and Young Adult Oncology, 2014, 3, 100-103.	1.3	0
94	Comparison of latino and non-Latino patients with Ewing sarcoma. Pediatric Blood and Cancer, 2014, 61, 233-237.	1.5	8
95	Development of Novel Tumorâ€Targeted Theranostic Nanoparticles Activated by Membraneâ€Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy. Small, 2014, 10, 566-575.	10.0	127
96	ACR Committee on Pediatric Imaging Research. Pediatric Radiology, 2014, 44, 1193-1194.	2.0	2
97	Basic science research in pediatric radiology â€" how to empower the leading edge of our field. Pediatric Radiology, 2014, 44, 935-939.	2.0	0
98	Ionising radiation-free whole-body MRI versus 18F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Lancet Oncology, The, 2014, 15, 275-285.	10.7	136
99	18F-FDG PET/CT scans for children and adolescents â€" Authors' reply. Lancet Oncology, The, 2014, 15, e244.	10.7	1
100	Pediatric Molecular Imaging. , 2014, , 571-595.		1
101	Role of diffusion-weighted imaging in differentiating benign and malignant pediatric abdominal tumors. Pediatric Radiology, 2013, 43, 836-845.	2.0	42
102	Magnetic Resonance Imaging of the Bone Marrow Contrast Media for Bone Marrow Imaging. Medical Radiology, 2013, , 355-365.	0.1	0
103	Comparison of the diagnostic value of MR imaging and ophthalmoscopy for the staging of retinoblastoma. European Radiology, 2013, 23, 1271-1280.	4.5	22
104	Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responses. Contrast Media and Molecular Imaging, 2013, 8, 281-288.	0.8	23
105	Magnetic Resonance Imaging and Tracking of Stem Cells. Methods in Molecular Biology, 2013, 1052, 167-176.	0.9	16
106	Iron Administration before Stem Cell Harvest Enables MR Imaging Tracking after Transplantation. Radiology, 2013, 269, 186-197.	7.3	62
107	Enhancing In Vivo Survival of Adipose-Derived Stromal Cells Through Bcl-2 Overexpression Using a Minicircle Vector. Stem Cells Translational Medicine, 2013, 2, 690-702.	3.3	30
108	Ferumoxytol: a new, clinically applicable label for stem-cell tracking in arthritic joints with MRI. Nanomedicine, 2013, 8, 1969-1983.	3.3	75

#	Article	IF	Citations
109	MR imaging of tumor-associated macrophages. OncoImmunology, 2012, 1, 507-509.	4.6	30
110	Dose Escalation Study of No-Carrier-Added ¹³¹I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial. Journal of Nuclear Medicine, 2012, 53, 1155-1163.	5.0	64
111	FDG PET/CT for the Evaluation of Normal Thymus, Lymphoma Recurrence, and Mediastinal Lymphoma in Pediatric Patients. Radiology, 2012, 264, 919-919.	7.3	8
112	Intravenous Ferumoxytol Allows Noninvasive MR Imaging Monitoring of Macrophage Migration into Stem Cell Transplants. Radiology, 2012, 264, 803-811.	7.3	54
113	A photonic crystal cavity-optical fiber tip nanoparticle sensor for biomedical applications. Applied Physics Letters, 2012, 100, .	3.3	29
114	Magnetic Resonance Imaging of Ferumoxide-Labeled Mesenchymal Stem Cells in Cartilage Defects: In Vitro and in Vivo Investigations. Molecular Imaging, 2012, 11, 7290.2011.00040.	1.4	36
115	Somatic Differentiation and MR Imaging of Magnetically Labeled Human Embryonic Stem Cells. Cell Transplantation, 2012, 21, 2555-2567.	2.5	27
116	Differentiation of Normal Thymus from Anterior Mediastinal Lymphoma and Lymphoma Recurrence at Pediatric PET/CT. Radiology, 2012, 262, 613-622.	7.3	50
117	High-Resolution MR Imaging of the Orbit in Patients with Retinoblastoma. Radiographics, 2012, 32, 1307-1326.	3.3	31
118	MR Imaging Features of Gadofluorine-Labeled Matrix-Associated Stem Cell Implants in Cartilage Defects. PLoS ONE, 2012, 7, e49971.	2.5	10
119	Engineering stem cells for treatment of osteochondral defects. Skeletal Radiology, 2012, 41, 1-4.	2.0	7
120	Magnetic resonance imaging of ferumoxide-labeled mesenchymal stem cells in cartilage defects: in vitro and in vivo investigations. Molecular Imaging, 2012, 11, 197-209.	1.4	28
121	MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles. Clinical Cancer Research, 2011, 17, 5695-5704.	7.0	262
122	Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle. Journal of Visualized Experiments, 2011, , e3482.	0.3	69
123	Labeling Human Mesenchymal Stem Cells with Fluorescent Contrast Agents: the Biological Impact. Molecular Imaging and Biology, 2011, 13, 3-9.	2.6	29
124	Labeling human embryonic stem-cell-derived cardiomyocytes for tracking with MR imaging. Pediatric Radiology, 2011, 41, 1384-1392.	2.0	14
125	A phase I study of zoledronic acid and lowâ€dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study. Pediatric Blood and Cancer, 2011, 57, 275-282.	1.5	43
126	Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging. Magnetic Resonance in Medicine, 2011, 65, 756-763.	3.0	39

#	Article	IF	Citations
127	Optical imaging of rheumatoid arthritis. International Journal of Clinical Rheumatology, 2011, 6, 67-75.	0.3	31
128	MR Signal Characteristics of Viable and Apoptotic Human Mesenchymal Stem Cells in Matrix-Associated Stem Cell Implants for Treatment of Osteoarthritis. Investigative Radiology, 2010, 45, 634-640.	6.2	36
129	Labeling Human Embryonic Stem Cell-Derived Cardiomyocytes with Indocyanine Green for Noninvasive Tracking with Optical Imaging: An FDA-Compatible Alternative to Firefly Luciferase. Cell Transplantation, 2010, 19, 55-65.	2.5	29
130	Uterine didelphys associated with obstructed hemivagina and ipsilateral renal anomaly (OHVIRA) syndrome. Radiology Case Reports, 2010, 5, 327.	0.6	24
131	Implantation of Ferumoxides Labeled Human Mesenchymal Stem Cells in Cartilage Defects. Journal of Visualized Experiments, 2010, , .	0.3	7
132	Accelerated stem cell labeling with ferucarbotran and protamine. European Radiology, 2010, 20, 640-648.	4.5	20
133	Ectopic ureter associated with uterine didelphys and obstructed hemivagina: preoperative diagnosis by MRI. Pediatric Radiology, 2010, 40, 358-360.	2.0	22
134	Unusual association of alveolar rhabdomyosarcoma with pancreatic metastasis: emerging role of PET-CT in tumor staging. Pediatric Radiology, 2010, 40, 1380-1386.	2.0	27
135	Radiological-pathological correlation of pleomorphic liposarcoma of the anterior mediastinum in a 17-year-old girl. Pediatric Radiology, 2010, 40, 68-70.	2.0	63
136	Indocyanine greenâ€"enhanced imaging of antigenâ€induced arthritis with an integrated optical imaging/radiography system. Arthritis and Rheumatism, 2010, 62, 2322-2327.	6.7	51
137	NK-cell tracking using non-invasive imaging modalities. , 2010, , 653-664.		0
138	Breast Cancers: MR Imaging of Folate-Receptor Expression with the Folate-Specific Nanoparticle P1133. Radiology, 2010, 255, 527-535.	7.3	130
139	Monitoring of Natural Killer Cell Immunotherapy Using Noninvasive Imaging Modalities. Cancer Research, 2010, 70, 6109-6113.	0.9	32
140	In Vivo Magnetic Resonance Imaging and Optical Imaging Comparison of Viable and Nonviable Mesenchymal Stem Cells with a Bifunctional Label. Molecular Imaging, 2010, 9, 7290.2010.00029.	1.4	28
141	Labeling human embryonic stem cell-derived cardiomyocytes with indocyanine green for noninvasive tracking with optical imaging: an FDA-compatible alternative to firefly luciferase. Cell Transplantation, 2010, 19, 55-65.	2.5	19
142	In vivo magnetic resonance imaging and optical imaging comparison of viable and nonviable mesenchymal stem cells with a bifunctional label. Molecular Imaging, 2010, 9, 278-90.	1.4	17
143	Phase I Trial of Oral Irinotecan and Temozolomide for Children With Relapsed High-Risk Neuroblastoma: A New Approach to Neuroblastoma Therapy Consortium Study. Journal of Clinical Oncology, 2009, 27, 1290-1296.	1.6	69
144	New Perspectives on Bone Marrow Contrast Agents and Molecular Imaging. Seminars in Musculoskeletal Radiology, 2009, 13, 145-156.	0.7	11

#	Article	IF	Citations
145	The influence of ferucarbotran on the chondrogenesis of human mesenchymal stem cells. Contrast Media and Molecular Imaging, 2009, 4, 165-173.	0.8	68
146	Relaxation effects of ferucarbotranâ€labeled mesenchymal stem cells at 1.5T and 3T: Discrimination of viable from lysed cells. Magnetic Resonance in Medicine, 2009, 62, 325-332.	3.0	48
147	Decreased aortic growth and middle aortic syndrome in patients with neuroblastoma after radiation therapy. Pediatric Radiology, 2009, 39, 1194-1202.	2.0	28
148	Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 23-36.	6.4	128
149	Pediatric liver tumors â€“ a pictorial review. European Radiology, 2009, 19, 209-219.	4.5	52
150	An optical imaging method to monitor stem cell migration in a model of immune-mediated arthritis. Optics Express, 2009, 17, 24403.	3.4	44
151	Optical imaging of the peri-tumoral inflammatory response in breast cancer. Journal of Translational Medicine, 2009, 7, 94.	4.4	6
152	MR Imaging of Pediatric Arthritis. Radiologic Clinics of North America, 2009, 47, 939-955.	1.8	3
153	MR Imaging of Pediatric Arthritis. Magnetic Resonance Imaging Clinics of North America, 2009, 17, 451-467.	1.1	31
154	Optical Imaging of Cellular Immunotherapy against Prostate Cancer. Molecular Imaging, 2009, 8, 7290.2009.00002.	1.4	64
155	Multiple Scalp Lesions in a Patient with Keratitis, Ichthyosis and Deafness Syndrome Mimicking Metastatic Squamous Cell Carcinoma on 18F-FDG PET/CT. Radiology Case Reports, 2009, 4, 218.	0.6	1
156	Optical imaging of cellular immunotherapy against prostate cancer. Molecular Imaging, 2009, 8, 15-26.	1.4	42
157	MR imaging of ovarian tumors using folate-receptor-targeted contrast agents. Pediatric Radiology, 2008, 38, 529-537.	2.0	38
158	Receptor imaging of pediatric tumors: clinical practice and new developments. Pediatric Radiology, 2008, 38, 1154-1161.	2.0	4
159	Improved fluorescence of indocyanine green in vitro and in vivo after simple cooling procedures. Contrast Media and Molecular Imaging, 2008, 3, 191-197.	0.8	9
160	Labeling Stem Cells with Fluorescent Dyes for non-invasive Detection with Optical Imaging. Journal of Visualized Experiments, 2008, , .	0.3	26
161	Cell tracking with optical imaging. European Radiology, 2008, 18, 2021-2032.	4.5	172
162	Detection of postoperative granulation tissue with an ICG-enhanced integrated OI-/X-ray System. Journal of Translational Medicine, 2008, 6, 73.	4.4	11

#	Article	IF	Citations
163	Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors. Nuclear Medicine and Biology, 2008, 35, 579-588.	0.6	69
164	Imaging Characteristics of DHOG, a Hepatobiliary Contrast Agent for Preclinical MicroCT in Mice. Academic Radiology, 2008, 15, 342-349.	2.5	26
165	Labeling hESCs and hMSCs with Iron Oxide Nanoparticles for Non-Invasive in vivo Tracking with MR Imaging. Journal of Visualized Experiments, 2008, , .	0.3	15
166	MR imaging of antigen-induced arthritis with a new, folate receptor-targeted contrast agent. Contrast Media and Molecular Imaging, 2007, 2, 72-81.	0.8	23
167	Long-Term Outcome and Toxicities of Intraoperative Radiotherapy for High-Risk Neuroblastoma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 858-864.	0.8	36
168	MR imaging of therapy-induced changes of bone marrow. European Radiology, 2007, 17, 743-761.	4.5	138
169	Cell labeling with the positive MR contrast agent Gadofluorine M. European Radiology, 2007, 17, 1226-1234.	4.5	47
170	Ultrasmall Supraparamagnetic Iron Oxide-Enhanced Magnetic Resonance Imaging of Antigen-Induced Arthritis. Investigative Radiology, 2006, 41, 45-51.	6.2	103
171	T1 and T2 relaxivity of intracellular and extracellular USPIO at 1.5T and 3T clinical MR scanning. European Radiology, 2006, 16, 738-745.	4.5	164
172	Ferumoxtran-10-enhanced MR imaging of the bone marrow before and after conditioning therapy in patients with non-Hodgkin lymphomas. European Radiology, 2006, 16, 598-607.	4.5	38
173	Optical imaging of experimental arthritis using allogeneic leukocytes labeled with a near-infrared fluorescent probe. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 998-1006.	6.4	35
174	MRI of arthritis: Comparison of ultrasmall superparamagnetic iron oxide vs. Gd-DTPA. Journal of Magnetic Resonance Imaging, 2006, 23, 720-727.	3.4	43
175	Imaging of Tumor Angiogenesis: Current Approaches and Future Prospects. Current Pharmaceutical Design, 2006, 12, 2661-2672.	1.9	42
176	The Choice of Region of Interest Measures in Contrast-Enhanced Magnetic Resonance Image Characterization of Experimental Breast Tumors. Investigative Radiology, 2005, 40, 349-354.	6.2	29
177	In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. European Radiology, 2005, 15, 4-13.	4.5	169
178	Detection of hepatocellular carcinoma: comparison of Gd-DTPA- and ferumoxides-enhanced MR imaging. European Radiology, 2005, 15, 895-903.	4.5	30
179	Mixture model approach to tumor classification based on pharmacokinetic measures of tumor permeability. Journal of Magnetic Resonance Imaging, 2005, 22, 549-558.	3.4	6
180	Optimization of Gadodiamide Concentration for MR Arthrography at 3 T. American Journal of Roentgenology, 2005, 184, 1754-1761.	2.2	31

#	Article	IF	Citations
181	Optimized Labeling of Hematopoietic Progenitor Cells derived from umbilical cord blood or peripheral blood with iron oxide contrast agents for in vivo depiction with MR imaging at 1.5 Tesla. Academic Radiology, 2005, 12, S38-S39.	2.5	0
182	Comparison of iron oxide labeling properties of hematopoietic progenitor cells from umbilical cord blood and from peripheral blood for subsequent in vivo tracking in a xenotransplant mouse model XXX1. Academic Radiology, 2005, 12, 502-510.	2.5	48
183	Ultrasmall Superparamagnetic Iron-Oxideâ€“enhanced MR Imaging of Normal Bone Marrow in Rodents: Original Research. Academic Radiology, 2005, 12, 1190-1197.	2.5	27
184	Migration of Iron Oxideâ€“labeled Human Hematopoietic Progenitor Cells in a Mouse Model: In Vivo Monitoring with 1.5-T MR Imaging Equipment. Radiology, 2005, 234, 197-205.	7.3	171
185	Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. European Radiology, 2004, 14, 1851-8.	4.5	231
186	Decrease in Tumor Apparent Permeability-Surface Area Product to a MRI Macromolecular Contrast Medium Following Angiogenesis Inhibition with Correlations to Cytotoxic Drug Accumulation. Microcirculation, 2004, 11, 387-396.	1.8	35
187	Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1312-21.	6.4	83
188	Macromolecular contrast agents for MR mammography: current status. European Radiology, 2003, 13, 354-365.	4.5	79
189	Highly efficient paramagnetic labelling of embryonic and neuronal stem cells. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1038-1044.	6.4	75
190	MR Imaging of Hepatic Metastases. Imaging Decisions (Berlin, Germany), 2003, 7, 19-28.	0.2	1
191	Macromolecular contrast medium (feruglose) versus small molecular contrast medium (gadopentetate) enhanced magnetic resonance imaging. Academic Radiology, 2003, 10, 1237-1246.	2.5	28
192	Detection and Quantification of Breast Tumor Necrosis with MR Imaging. Academic Radiology, 2003, 10, 484-490.	2.5	48
193	Quantification of Breast Tumor Microvascular Permeability with Feruglose-enhanced MR Imaging: Initial Phase II Multicenter Trial. Radiology, 2003, 229, 885-892.	7.3	79
194	Targeting of Hematopoietic Progenitor Cells with MR Contrast Agents. Radiology, 2003, 228, 760-767.	7.3	196
195	FDGâ€“PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Annals of Oncology, 2002, 13, 157-160.	1.2	173
196	Comparison between Gadopentetate and Feruglose (Clariscanâ„¢)-Enhanced MR-Mammography. Academic Radiology, 2002, 9, S343-S347.	2.5	5
197	Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin's lymphoma: differentiation between tumor infiltration and hypercellular bone marrow. European Radiology, 2002, 12, 1557-1566.	4.5	85
198	FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: Comparison with spiral CT. Annals of Oncology, 2001, 12, 479-486.	1.2	188

#	Article	IF	Citations
199	Carboxymethyldextran-A2-Gd-DOTA enhancement patterns in the abdomen and pelvis in an animal model. European Radiology, 2001, 11, 1276-1284.	4.5	9
200	Whole-Body MR Imaging for Detection of Bone Metastases in Children and Young Adults. American Journal of Roentgenology, 2001, 177, 229-236.	2.2	431
201	Quantitative gadopentetate-enhanced MRI of breast tumors: Testing of different analytic methods. Magnetic Resonance in Medicine, 2000, 44, 915-924.	3.0	38
202	Assessing permeability alterations of the bloodâ€“bone marrow barrier due to total body irradiation: in vivo quantification with contrast enhanced magnetic resonance imaging. Bone Marrow Transplantation, 2000, 25, 71-78.	2.4	29
203	FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1305-1311.	2.1	272
204	Evaluation of the Accuracy of Gadobenate Dimeglumine-Enhanced MR Imaging in the Detection and Characterization of Focal Liver Lesions. American Journal of Roentgenology, 2000, 175, 1111-1120.	2.2	88
205	Focal Liver Lesions: Evaluation of the Efficacy of Gadobenate Dimeglumine in MR Imagingâ€”A Multicenter Phase III Clinical Study. Radiology, 2000, 215, 727-736.	7.3	188
206	Comparison of gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging. Academic Radiology, 2000, 7, 934-944.	2.5	27
207	CT of Metal Implants: Reduction of Artifacts Using an Extended CT Scale Technique. Journal of Computer Assisted Tomography, 2000, 24, 165-172.	0.9	107
208	Monitoring radiation-induced changes in bone marrow histopathology with ultra-small superparamagnetic iron oxide (USPIO)-enhanced MRI. Journal of Magnetic Resonance Imaging, 1999, 9, 643-652.	3.4	50
209	Quantification of the extraction fraction for gadopentetate across breast cancer capillaries. Magnetic Resonance in Medicine, 1998, 40, 537-543.	3.0	84
210	Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. Pediatric Radiology, 1998, 28, 67-78.	2.0	78
211	High Resolution MRI of Small Joints: Impact of Spatial Resolution on Diagnostic Performance and SNR. Magnetic Resonance Imaging, 1998, 16, 147-155.	1.8	77
212	Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.. American Journal of Roentgenology, 1998, 171, 941-949.	2.2	244
213	Macromolecular contrast mediaâ€”enhanced MRI estimates of microvascular permeability correlate with histopathologic tumor grade. Academic Radiology, 1998, 5, S2-S5.	2.5	19
214	Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. European Radiology, 1997, 7, 275-280.	4.5	158
215	Evaluation of myelination and myelination disorders with turbo inversion recovery magnetic resonance imaging. European Radiology, 1997, 7, 1478-1484.	4.5	8
216	Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence.. Radiology, 1996, 199, 177-183.	7.3	294

#	Article	IF	Citations
217	Clinical results with Resovist: a phase 2 clinical trial.. Radiology, 1995, 195, 489-496.	7.3	181
218	Pediatric tumors. , 0, , 181-219.		1
219	Fibromuscular dysplasia. , 0, , 158-161.		0
220	Lymphoma: pulmonary manifestations. , 0, , 56-61.		0
221	Medial malleolus avulsion fracture. , 0, , 359-361.		0
222	Pleuropulmonary blastoma. , 0, , 36-39.		0
223	PHACES syndrome (Posterior fossa malformations, Hemangiomas of the face, Arterial anomalies,) Tj ETQq1 1 0.784314 rgBT /Overloc		0
224	Lipoid pneumonia. , 0, , 33-35.		0
225	Opsoclonusâ€“myoclonus due to underlying ganglioneuroblastoma. , 0, , 53-55.		0
226	Bronchopulmonary malformation: hybrid lesions. , 0, , 79-86.		0
227	Nephroblastomatosis. , 0, , 260-263.		0
228	Neuroendocrine cell hyperplasia of infancy (NEHI). , 0, , 40-43.		0
229	Thymus: normal variations. , 0, , 66-71.		0
230	Clubfoot. , 0, , 336-338.		0
231	Gastroschisis. , 0, , 322-325.		0
232	Ectopic cervical thymus. , 0, , 20-22.		0
233	Fibromatosis colli. , 0, , 7-9.		0
234	Tetralogy of Fallot with pulmonary atresia. , 0, , 94-97.		0

#	Article	IF	Citations
235	Meconium ileus. , 0, , 237-244.		0
236	Thyroid colloid cyst. , 0, , 289-290.		1
237	Fetal osteogenesis imperfecta. , 0, , 326-328.		0
238	Trilateral retinoblastoma. , 0, , 1-6.		0
239	Labyrinthitis ossificans. , 0, , 14-15.		0
240	Branchio-oto-renal syndrome. , 0, , 16-17.		0
241	X-linked adrenoleukodystrophy. , 0, , 23-24.		0
242	Endobronchial foreign body recognition. , 0, , 44-47.		0
243	Chronic esophageal foreign body. , 0, , 48-52.		0
244	Acute and subacute pneumonia in childhood: tuberculosis. , 0, , 62-65.		0
245	Airleak in the neonate. , 0, , 72-78.		0
246	Lymphatic abnormality in the pediatric chest. , 0, , 87-93.		0
247	Left pulmonary artery sling. , 0, , 98-101.		0
248	Vascular ring. , 0, , 102-106.		0
249	Scimitar syndrome. , 0, , 107-110.		0
250	Portosystemic shunt and portopulmonary syndrome. , 0, , 111-116.		0
251	Aortic coarctation and interrupted aortic arch. , 0, , 117-121.		0
252	Ebsteinâ€™s anomaly. , 0, , 122-126.		0

#	Article	IF	Citations
253	Transposition of the great arteries. , 0, , 127-134.		0
254	Total anomalous pulmonary venous return. , 0, , 135-140.		0
255	Aberrant left coronary artery arising from the pulmonary artery. , 0, , 141-146.		0
256	Lower extremity ischemia due to homocystinuria. , 0, , 147-150.		0
257	Iatrogenic pathology masquerading as an artifact. , 0, , 151-157.		0
258	Traumatic vertebral arteriovenous fistulae. , 0, , 162-168.		0
259	Colonic perforation during intussusception reduction. , 0, , 169-172.		0
260	Juvenile nasopharyngeal angioma. , 0, , 173-176.		0
261	Small bowel fistula complicating perforated appendicitis: successful treatment with tissue adhesive. , 0, , 177-180.		0
262	Extrahepatic collateral arterial supply to hepatocellular carcinoma. , 0, , 181-182.		0
263	Use of a curved needle to access an otherwise inaccessible abscess. , 0, , 183-187.		0
264	Umbilical venous catheter malposition. , 0, , 188-192.		0
265	Middle aortic syndrome. , 0, , 193-195.		0
266	Ruptured appendicitis mimicking an intussusception. , 0, , 196-200.		0
267	Choledochal cyst. , 0, , 201-204.		0
268	Henochâ€“SchÃ¶nlein purpura. , 0, , 205-206.		0
269	Mesenchymal hamartoma of the liver. , 0, , 211-214.		0
270	Midgut volvulus. , 0, , 218-221.		0

#	Article	IF	Citations
271	Foveolar hyperplasia: post prostaglandin therapy. , 0, , 222-225.		0
272	Pneumatosis cystoides intestinalis. , 0, , 226-228.		0
273	Desmoplastic small round cell tumor. , 0, , 229-230.		0
274	Post-transplantation lymphoproliferative disorder. , 0, , 231-233.		0
275	Traumatic pancreatic injury. , 0, , 234-236.		0
276	Renal cysts in tuberous sclerosis. , 0, , 245-247.		0
277	Prune belly syndrome. , 0, , 248-251.		0
278	Renal vein thrombosis. , 0, , 252-254.		0
279	Acute bacterial pyelonephritis. , 0, , 255-256.		0
280	Ectopic ureterocele. , 0, , 257-259.		0
281	Urachal mass. , 0, , 264-268.		0
282	Wilmsâ€™ tumor. , 0, , 269-275.		0
283	Ureteropelvic junction obstruction. , 0, , 276-280.		0
284	Oxalosis in an 11-year-old boy. , 0, , 281-284.		0
285	Pediatric Gravesâ€™ disease. , 0, , 285-286.		0
286	Thyroglossal duct cyst. , 0, , 287-288.		0
287	Adrenal hemorrhage. , 0, , 291-293.		0
288	Ovarian torsion in childhood. , 0, , 297-302.		0

#	Article	IF	Citations
289	Torsion of the appendix testis. , 0, , 303-306.		0
290	Intratesticular neoplasms. , 0, , 307-312.		0
291	Fetal lymphatic malformation. , 0, , 313-315.		0
292	Anal atresia with urorectal fistula. , 0, , 316-318.		0
293	Cystic dysplasia of the kidneys. , 0, , 319-321.		0
294	Hydrops fetalis. , 0, , 334-335.		0
295	Leggâ€“Calveâ€“Perthes disease. , 0, , 343-346.		0
296	Langerhans cell histiocytosis: MRI/PET for diagnosis and treatment monitoring. , 0, , 350-353.		0
297	Triplane fracture. , 0, , 362-364.		0
298	Campomelic dysplasia. , 0, , 374-376.		0
299	Type II collagenopathy (hypochondrogenesis). , 0, , 377-379.		0
300	Morel-LavallÃ©e lesions. , 0, , 380-383.		1
301	Infantile myofibromatosis. , 0, , 384-386.		0
302	Osteochondritis dissecans of the capitellum. , 0, , 387-388.		0
303	Chest wall sarcoma. , 0, , 370-373.		0
304	Stem Cell Tracking. , 0, , 65-75.		0